Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Cefodizime is a third-generation cephalosporin antibiotic characterized by its broad-spectrum activity against both Gram-positive and Gram-negative bacteria. Its molecular formula is C23H25N9O10S4, and it carries the CAS registry number 76812-84-5. This unique beta-lactam compound features a distinctive thiazolidine ring structure modified with a diaminotriazine side chain, which significantly enhances its stability against various beta-lactamases produced by resistant bacterial strains.
The primary clinical utility of Cefodizime lies in the treatment of severe infections caused by multidrug-resistant pathogens. It demonstrates exceptional efficacy against common respiratory tract infections, including pneumonia and bronchitis, as well as urinary tract infections, septicemia, and intra-abdominal infections. Unlike many other cephalosporins, Cefodizime possesses a strong ability to penetrate deep tissues and maintains high concentrations in serum and bile, making it particularly effective for systemic and deep-seated infections. Its mechanism of action involves the inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), ultimately leading to cell lysis and death.
A notable advantage of this agent is its potent immunomodulatory properties. Research indicates that Cefodizime can enhance the immune response by stimulating macrophage function and increasing cytokine production, thereby aiding the body in fighting off infections more effectively. This dual action of direct antibacterial activity and immune system support makes it a valuable therapeutic option in hospital settings where resistance patterns are complex. Furthermore, it exhibits low cross-resistance with other beta-lactam antibiotics, offering a viable alternative when first-line treatments fail. The drug is typically administered intravenously or intramuscularly due to its poor oral bioavailability. While generally well-tolerated, potential side effects may include gastrointestinal disturbances, skin rashes, and transient elevations in liver enzymes. Overall, Cefodizime represents a critical advancement in antimicrobial therapy, providing robust coverage against challenging bacterial pathogens while supporting host defense mechanisms in critically ill patients.